Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations
Autor: | Maria Flavia Di Renzo, Mauro Salizzoni, Lorenzo Capussotti, Stefania Gastaldi, Enzo Medico, Livio Trusolino, Timothy Perera, Alberto Pisacane, Davide Corà, Davide Torti, Gianluca Paraluppi, Paolo Massucco, Dimitrios Siatis, Andrea Bertotti, Francesco Galimi, Francesca Maione, Mauro Risio, Claudio Isella, Dario Ribero, Ezio David, Federica Gonella, Bruno Torchio, Paolo M. Comoglio, Andrea Muratore, Francesco Sassi |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
Cancer Research Colorectal cancer HEPATOCYTE GROWTH-FACTOR Mice SCID PRIMARY COLON-CANCER Nod Biomarkers Pharmacological Mice Mice Inbred NOD LIVER METASTASES KINASE INHIBITORS BREAST-CANCER AMPLIFICATION IDENTIFICATION PROTOONCOGENE CHEMOTHERAPY SENSITIVITY Medicine Neoplasm Metastasis Aged 80 and over Hepatocyte Growth Factor Middle Aged Proto-Oncogene Proteins c-met Gene Expression Regulation Neoplastic Real-time polymerase chain reaction Oncology Female Hepatocyte growth factor Colorectal Neoplasms medicine.drug In silico Antineoplastic Agents Downregulation and upregulation Biomarkers Tumor Animals Humans Receptors Growth Factor Protein Kinase Inhibitors Aged Messenger RNA business.industry Gene Expression Profiling Carcinoma Cancer medicine.disease Xenograft Model Antitumor Assays Immunology Trans-Activators Cancer research business Transcription Factors |
Zdroj: | Clinical Cancer Research. 17:3146-3156 |
ISSN: | 1557-3265 1078-0432 |
Popis: | Purpose: We determined the gene copy numbers for MET, for its transcriptional activator MACC1 and for its ligand hepatocyte growth factor (HGF) in liver metastases from colorectal carcinoma (mCRC). We correlated copy numbers with mRNA levels and explored whether gain and/or overexpression of MET and MACC1 predict response to anti-Met therapies. Finally, we assessed whether their genomic or transcriptional deregulation correlates with pathologic and molecular parameters of aggressive disease. Experimental Design: One hundred three mCRCs were analyzed. Copy numbers and mRNA were determined by quantitative PCR (qPCR). Thirty nine samples were implanted and expanded in NOD (nonobese diabetic)/SCID (severe combined immunodeficient) mice to generate cohorts that were treated with the Met inhibitor JNJ-38877605. In silico analysis of MACC1 targets relied on genome-wide mapping of promoter regions and on expression data from two CRC datasets. Results: No focal, high-grade amplifications of MET, MACC1, or HGF were detected. Chromosome 7 polysomy and gain of the p-arm were observed in 21% and 8% of cases, respectively, and significantly correlated with higher expression of both Met and MACC1. Met inhibition in patient-derived xenografts did not modify tumor growth. Copy number gain and overexpression of MACC1 correlated with unfavorable pathologic features better than overexpression of Met. Bioinformatic analysis of putative MACC1 targets identified elements besides Met, whose overexpression cosegregated with aggressive forms of colorectal cancer. Conclusions: Experiments in patient-derived xenografts suggest that mCRCs do not rely on Met genomic gain and/or overexpression for growth. On the basis of pathologic correlations and bioinformatic analysis, MACC1 could contribute to CRC progression through mechanisms other than or additional to Met transcriptional upregulation. Clin Cancer Res; 17(10); 3146–56. ©2011 AACR. |
Databáze: | OpenAIRE |
Externí odkaz: |